NASDAQ
11.22USD
-0.08 (-0.71%)
We have scored 17 news catalysts on Kura Oncology, Inc. (KURA) over the past 12 months. The biggest single-day move next to one of them came Mar 7, 2026, when KURA closed +5.3%: “Kura Oncology Q4 Earnings Call Highlights”. Coverage across the window leans positive (average ticker sentiment +0.68). Most of the impact sits in forward growth expectations and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
994.7M
P/E
—
EPS
—
Beta
0.38
52W range
7.358-13.9
Day range
11.18–11.52
Open
11.31
Prev close
11.30
Volume
874.8K
Avg volume
1.9M
Dividend
0.00
IPO
2015-09-16
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Kura Oncology, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for KURA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
